奥美沙坦酯联合氨氯地平治疗原发性高血压伴左心室肥厚的临床效果  

Clinical effect of olmesartan medoxomil combined with amlodipine in the treatment of essential hypertension with left ventricular hypertrophy

作　　者：袁伟 付存玉 YUAN Wei;FU Cunyu(Linyi Central Hospital,Shandong Province,Linyi 276400,China)

机构地区：[1]山东省临沂市中心医院,276400

出　　处：《临床合理用药杂志》2022年第26期5-7,11,共4页Chinese Journal of Clinical Rational Drug Use

摘　　要：目的观察奥美沙坦酯联合氨氯地平治疗原发性高血压伴左心室肥厚的临床效果。方法选取2018年1月—2020年10月临沂市中心医院收治的原发性高血压伴左心室肥厚患者96例,采用随机数字表法分为观察组和对照组,每组48例。对照组给予氨氯地平治疗,观察组则采用奥美沙坦酯联合氨氯地平治疗,2组均连续治疗6个月。比较2组患者治疗总有效率,治疗前后血压[收缩压(SBP)、舒张压(DBP)]、左心室肥厚指标[左心室后壁厚度(LVPWT)、室间隔厚度(IVST)、左心室质量指数(LVMI)]变化,药物不良反应。结果观察组患者治疗总有效率为95.83%,高于对照组的79.17%(χ^(2)=6.095,P=0.014);治疗6个月后,2组SBP、DBP均较治疗前降低,2组LVPWT、IVST较治疗前缩小,LVMI较治疗前下降,且观察组上述指标改善优于对照组(P均<0.01);2组不良反应总发生率比较差异无统计学意义(χ^(2)=0.381,P=0.537),2组均未出现肝肾功能损伤等严重不良反应。结论奥美沙坦酯联合氨氯地平治疗原发性高血压伴左心室肥厚患者效果显著,能够显著降低血压水平,逆转左心室肥厚,且安全性高,值得临床推广应用。Objective To observe the clinical effect of olmesartan medoxomil combined with amlodipine in the treatment of essential hypertension with left ventricular hypertrophy.Methods 96 patients with essential hypertension with left ventricular hypertrophy treated in Linyi Central Hospital from January 2018 to October 2020 were randomly divided into observation group and control group,with 48 cases in each group.The control group was treated with amlodipine,while obser⁃vation group was treated with olmesartan medoxomil and amlodipine.All the patients were treated for 6 months.The clinical efficacy,incidence of adverse reactions,blood pressure(DBP and SBP),indicators of left ventricular hypertrophy(LVPWT,IVST,LVMI)before and after treatment were compared between the two groups.Results The total effective rate of patients in the observation group was 95.83%,which was higher than 79.17%in the control group(χ^(2)=6.095,P=0.014).After 6 months of treatment,the levels of SBP and DBP of the two groups were lower than those before treatment,and the SBP and DBP of the observation group were lower than those of the control group(all P<0.01).Compared with before treatment,LVPWT and IVST in both groups decreased,LVMI decreased,and the improvement of the above indicators in the observation group was better than that in the control group(all P<0.01).There was no significant difference in the total incidence of adverse reactions between the two groups(χ^(2)=0.381,P=0.537),and there were no serious adverse reactions such as liver and kidney function damage in both groups.Conclusion Olmesartan medoxomil combined with amlodipine in the treatment of essential hypertension with left ventricular hypertroph can effectively reduce the blood pressure,reverse left ventricular hyper⁃trophy,and has a good clinical effect,with higher safe.It is worthy of popularization and application.

关 键 词：原发性高血压 左心室肥厚 奥美沙坦酯 氨氯地平 治疗效果 

分 类 号：R544.11[医药卫生—心血管疾病]